How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) posted its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative trailing twelve-month return on equity of 272.70% and a negative net margin of 242.60%.

When did Cytori Therapeutics' stock split?

Cytori Therapeutics's stock reverse split on the morning of Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cytori Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS) , Inovio Pharmaceuticals (INO) , Shire (SHPG) , Bank of America (BAC) , Exelixis (EXEL) , Athersys (ATHX) , BCE (BCE) , Celldex Therapeutics (CLDX) , Synergy Pharmaceuticals (SGYP) and Novavax (NVAX) .

NASDAQ:CYTX

Cytori Therapeutics (CYTX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CYTX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.67
▼
$1.80
50-Day Range: $0.20
▼
$0.21
52-Week Range: $0.20
▼
$0.75

Volume: 27,933 shs
Average Volume: 915,302 shs
Market Capitalization: $39.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Cytori Therapeutics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Cytori Therapeutics Stock (NASDAQ:CYTX)

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

CYTX Stock News Headlines

February 9, 2024 | investing.com

Checkpoint Therapeutics Inc (CKPT)

November 4, 2023 | morningstar.com

Sage Therapeutics Inc SAGE

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

September 27, 2023 | thestreet.com

5 Biotech Stocks Under $10 Blasting Higher

October 16, 2022 | finance.yahoo.com

Women’s Health Therapeutics Market Research Report by Type, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

August 29, 2022 | thestreet.com

8 Stocks Under $10 Ripping Higher

See More Headlines

Receive CYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/14/2019
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & Medical Instruments
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:CYTX
CUSIP: 23283K10
CIK: 1095981
Web: www.cytori.com
Phone: 858-458-0900
Fax: N/A
Employees: 37
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,630,000.00
Net Margins: -242.60%
Pretax Margin: N/A
Return on Equity: -272.70%
Return on Assets: -56.23%

Debt

Debt-to-Equity Ratio: 0.39
Current Ratio: 0.46
Quick Ratio: 0.30

Sales & Book Value

Annual Sales: $3.67 million
Price / Sales: 10.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.35 per share
Price / Book: 5.04

Miscellaneous

Outstanding Shares: 22,160,000
Free Float: N/A
Market Cap: $39.11 million
Optionable: Not Optionable
Beta: 1.96

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Marc H. Hedrick
President, Chief Executive Officer & Director
Gary S. Titus
Chief Financial Officer
Mark T. Marino
Chief Medical Officer & Senior Vice President
John K. Fraser
Chief Scientist
Russ Havranek
VP-Global Marketing & Business Development

Key Competitors

View All Competitors

CYTX Stock Analysis - Frequently Asked Questions

How were Cytori Therapeutics' earnings last quarter?: Cytori Therapeutics Inc (NASDAQ:CYTX) posted its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative trailing twelve-month return on equity of 272.70% and a negative net margin of 242.60%.
When did Cytori Therapeutics' stock split?: Cytori Therapeutics's stock reverse split on the morning of Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Cytori Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), Exelixis (EXEL), Athersys (ATHX), BCE (BCE), Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP) and Novavax (NVAX).

This page (NASDAQ:CYTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cytori Therapeutics (CYTX) Stock Price, News & Analysis

About Cytori Therapeutics Stock (NASDAQ:CYTX)

CYTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CYTX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info